BioPharmSignal logoBioPharmSignal

Biotech News

Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451

Sana Biotechnology (SANA)Sana BiotechnologyPartnership

Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes Initial efforts will include processes and protocols to improve handling of and clinical care involving SC451, a cell

Related news

SANASana Biotechnology2026-07-13 12:00 EST

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

SANASana Biotechnology2026-03-13 13:00 EST

Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

TSHATaysha Gene Therapies2026-08-03 12:00 EST

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

GSKGSK plc2026-05-11 12:00 EST

GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch

OCGNOcugen2026-07-13 11:02 EST

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

TSHATaysha Gene Therapies2026-08-04 20:00 EST

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

View all latest news

Sana Biotechnology

Engineered Cell Therapies Sana Biotechnology develops engineered cells intended to repair or replace damaged biology while overcoming immune rejection. Its platform spans ex vivo cell replacement and in vivo delivery technologies. SC451 Islet-Cell Therapy SC451 is a gene-modified, stem-cell-derived pancreatic islet-cell candidate...

Recent company news

SANASana Biotechnology2026-07-13 12:00 EST

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

SANASana Biotechnology2026-07-01 13:00 EST

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

SANASana Biotechnology2026-05-15 13:00 EST

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

SANASana Biotechnology2026-05-12 20:05 EST

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

Stock data

Close
3.41 USD
Market cap
901.66M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States